NYSE:BVS Bioventus (BVS) Stock Price, News & Analysis $11.59 -0.10 (-0.86%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Bioventus alerts: Email Address About Bioventus Stock (NYSE:BVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioventus alerts:Sign Up Key Stats Today's Range$11.56▼$12.0350-Day Range$6.26▼$11.6952-Week Range$2.82▼$12.03Volume393,901 shsAverage Volume381,536 shsMarket Capitalization$917.53 millionP/E RatioN/ADividend YieldN/APrice Target$10.33Consensus RatingBuy Company OverviewBioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Read More… “I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (Ad)Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.Go here for the full details now. Bioventus Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 51st PercentileBioventus scored higher than 51% of companies evaluated by MarketBeat, and ranked 679th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingBioventus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioventus has only been the subject of 2 research reports in the past 90 days.Read more about Bioventus' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth12.50% Earnings GrowthEarnings for Bioventus are expected to grow by 12.50% in the coming year, from $0.40 to $0.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioventus is -33.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioventus is -33.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioventus has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bioventus' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BVS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioventus does not currently pay a dividend.Dividend GrowthBioventus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BVS. News and Social Media3.9 / 5News Sentiment1.00 News SentimentBioventus has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bioventus this week, compared to 1 article on an average week.Search Interest9 people have searched for BVS on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows8 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Bioventus insiders have bought 970.84% more of their company's stock than they have sold. Specifically, they have bought $902,025.00 in company stock and sold $84,235.00 in company stock.Percentage Held by Insiders32.90% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bioventus' insider trading history. Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Email Address BVS Stock News HeadlinesBioventus Inc. (NYSE:BVS) Director John A. Bartholdson Acquires 25,500 SharesAugust 21, 2024 | insidertrades.comBioventus Inc. (NYSE:BVS) Director John A. Bartholdson Acquires 80,000 SharesAugust 21, 2024 | insidertrades.comWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 19, 2024 | Porter & Company (Ad)Bioventus and Pool have been highlighted as Zacks Bull and Bear of the DayAugust 29, 2024 | finance.yahoo.comBioventus Inc. (BVS) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | seekingalpha.comHealing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024August 12, 2024 | seekingalpha.comBioventus to Present at the Canaccord Genuity 44th Annual Global Growth ConferenceAugust 7, 2024 | globenewswire.comYum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On TuesdayAugust 6, 2024 | benzinga.comSee More Headlines BVS Stock Analysis - Frequently Asked Questions How have BVS shares performed this year? Bioventus' stock was trading at $5.27 on January 1st, 2024. Since then, BVS shares have increased by 119.9% and is now trading at $11.59. View the best growth stocks for 2024 here. How were Bioventus' earnings last quarter? Bioventus Inc. (NYSE:BVS) announced its earnings results on Tuesday, August, 6th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.12. The business earned $151.22 million during the quarter, compared to analyst estimates of $137.70 million. Bioventus had a positive trailing twelve-month return on equity of 14.39% and a negative net margin of 7.82%. When did Bioventus IPO? Bioventus (BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO. Who are Bioventus' major shareholders? Bioventus' top institutional shareholders include Nantahala Capital Management LLC (6.74%), Renaissance Technologies LLC (0.64%), Marshall Wace LLP (0.42%) and American Century Companies Inc. (0.21%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, William A Hawkins, Anthony P Bihl III, Anthony D'adamio, John Nosenzo, Mark Leonard Singleton, Kenneth Michael Reali and Katrina J Church. View institutional ownership trends. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/06/2024Today9/19/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:BVS CUSIPN/A CIK1665988 Webwww.bioventus.com Phone919-474-6700FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$10.33 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside-12.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E Ratio29.48 P/E GrowthN/ANet Income$-156,230,000.00 Net Margins-7.82% Pretax Margin-11.39% Return on Equity14.39% Return on Assets3.83% Debt Debt-to-Equity Ratio1.82 Current Ratio1.33 Quick Ratio0.96 Sales & Book Value Annual Sales$536.89 million Price / Sales1.74 Cash Flow$0.89 per share Price / Cash Flow13.31 Book Value$2.80 per share Price / Book4.21Miscellaneous Outstanding Shares79,166,000Free Float53,120,000Market Cap$933.37 million OptionableNot Optionable Beta0.89 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSE:BVS) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.